Funding
Series B · Biotech

ILiAD Biotechnologies raises $115m Series B for pertussis vaccine

RA Capital Management, Janus Henderson Investors and other investors participated in the financing.

Updated Oct 16, 2026By RoundOS Funding desk

ILiAD Biotechnologies raised $115 million in Series B financing on February 10. Participants included RA Capital Management, Janus Henderson Investors, BNP Paribas Asset Management Alts and AI Life Sciences. The company develops the BPZE1 pertussis vaccine candidate.

Funding history

Series B · This round$115M

Sources

  1. ILiAD Biotechnologiesprojectstartups.com
  2. businesswire.com

Similar rounds

All Biotech rounds →
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Warp Sciences

Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States.

$215MSeries A · Oct 22, 2026
SEGNOS

SEGNOS develops magnetic-particle materials and diagnostic technologies for blood testing.

UndisclosedPre-Series A · Oct 22, 2026

Related